Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Definitive HealthcareDH +1.23%49 Debt-to-EBITDA is -0.24 as of Mar. 2026. GuruFocus rates DH with a GF Score™ of 49/100 and a GF Value™ of $4.43 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Definitive Healthcare ranks worse than 209204.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Definitive Healthcare's Debt-to-EBITDA or its related term are showing as below:
DH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.22 Med: 5.04 Max: 11.73
Current: -0.99
During the past 7 years, the highest Debt-to-EBITDA Ratio of Definitive Healthcare was 11.73. The lowest was -1.22. And the median was 5.04.
DH's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs DH: -0.99
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Definitive Healthcare Debt-to-EBITDA Related Terms
Definitive Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Definitive Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Definitive Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Definitive Healthcare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Definitive Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Definitive Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Definitive Healthcare (DH) has a Debt-to-EBITDA of -0.24 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Definitive Healthcare. According to the industry distribution chart, Definitive Healthcare ranks #999999 out of 478 companies in the Healthcare Providers & Services industry.
Is Definitive Healthcare's Debt-to-EBITDA too high?
Definitive Healthcare's current Debt-to-EBITDA is -0.24. Based on the distribution chart, Definitive Healthcare ranks #999999 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Definitive Healthcare has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Definitive Healthcare's Debt-to-EBITDA compare to DRIO and CCLD?
According to the Healthcare Providers & Services industry distribution chart, Definitive Healthcare ranks #999999 out of 478 companies for Debt-to-EBITDA. This places Definitive Healthcare in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Definitive Healthcare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Definitive Healthcare's current Debt-to-EBITDA is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definitive Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Definitive Healthcare (DH) is currently considered Possible Value Trap. The stock's GF Value™ is $4.43, compared to a current price of $0.81 — trading 81.6% below its estimated fair value. The current Debt-to-EBITDA is -0.24. Definitive Healthcare's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Definitive Healthcare (DH), the current Debt-to-EBITDA is -0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Definitive Healthcare (DH) Overvalued in 2026?
Based on GuruFocus' analysis, Definitive Healthcare stock appears to be undervalued.
The current stock price of $0.81 is trading 81.6% below its estimated GF Value™ of $4.43.
GuruFocus considers Definitive Healthcare to be Possible Value Trap.
Key valuation signals for DH:
Debt-to-EBITDA: -0.24
GF Value™: $4.43 vs. price of $0.81 (81.6% below fair value)
No single metric tells the full story. See the DH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
49GF Score
Get the complete analysis for DH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DH has been successfully added to your 
